Keywords
How to Cite
Abstract
The purpose of the study was to evaluate the prognostic value of the detection of tumor cells in the bone marrow (BM) in children with neuroblastoma (NB) by flow cytometry. The detection of tumor cells was performed in BM of 51 patients with NB (24 boys and 27 girls) aged from 6 days to 15 years (median - 1 year 3 months). Flow cytometry allowed determining NB cells in BM in a much larger number of cases than cytomorphology (49.0 % and 29.4 % of patients, respectively). Patients, in whom NB cells were not detected in BM by flow cytometry, had significantly better event-free and overall survival rates as well as progression free survival (83,5 %, 87,7 % and 86,8 %, respectively) compared with those in whom immunophenotyping revealed the tumor cells (28,0 %, 35,87 % and 34,3 %, respectively). The prognostic value of the detection of BM lesion by flow cytometry was also confirmed in selected groups of patients with other criteria of stratification. Therefore the detection of tumor cells in BM by flow cytometry could potentially be considered in conjunction with other factors in choosing treatment strategy in patients with NB.References
Bozzi, F. Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry / F Bozzi, F. Gambirasio, R. Luksch et al. // Anticancer Res. - 2006. - Vol. 26. - P. 3281-3288.
Brodeur, G.M. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment / G.M. Brodeur, J. Pritchard, F. Berthold et al. // J. Clin. Oncol. - 1993. - Vol. 11. - P. 1466-1477.
Brodeur, G.M. Neuroblastoma. / G.M. Brodeur, T. Sawada, Y. Tsuchida. - New York: Elsevier Science, 2000. - P. 21.
Cai, J.Y. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration / J.Y. Cai, C. Pan, Y.J. Tang et al. // Am. J. Clin. Oncol. - 2012. - Vol. 35. - P. 275-278.
Cheung, N.K. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies / N.K. Cheung, D.D. Von Hoff, S.E. Strandjord, P.F. Coccia // J. Clin. Oncol. - 1986. - Vol. 3. - P. 363-369.
Cheung, I.Y. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers / I.Y. Cheung, D. Barber, N.K. Cheung // Clin. Cancer Res. - 1998. - Vol. 4. - P. 2801-2805.
Cheung, I.Y. Quantification of marrow disease in neuroblastoma by real-time reverse transcription-PCR / I.Y. Cheung, N.K.V. Cheung // Clin. Cancer Res. - 2001. - Vol. 7. - P. 1698-1705.
Cohn, S.L. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report / S.L. Cohn, A.D. Pearson, W.B. London et al. // J. Clin. Oncol. - 2009. - Vol. 2. - P. 289-297.
Cox, D.R. Regression models and life-tables / D.R. Cox // J. R. Stat. Soc. B. - 1972. - Vol. 34. - P. 187-220.
Esser, R. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR / R. Esser, W. Glienke, K. Bochennek et al. // Klin. Padiatr. - 2011. - Vol. 6. - P. 326-331.
Grovas, A. The National Cancer Data Base report on patterns of childhood cancers in the United States / A. Grovas, A. Fremgen, A. Rauck et al. // Cancer. - 1997. - Vol. 12. - P. 2321-2332.
Ifversen, M.R.S. Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma / M.R.S. Ifversen, B. Kagedal, L.D. Christensen et al. // Int. J. Oncol. - 2005. - Vol. 27. - P. 121-129.
Kaplan, E. Non-parametric estimation from incomplete observations / E. Kaplan, P. Meier // J. Am. Stat. Assoc. - 1958. - Vol. 53. - P. 457-481.
Ladenstein, R. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study // R. Ladenstein, D. Valteau-Couanet, P. Brock et al. // J. Clin. Oncol. - 2010. - Vol. 28. - P. 3516-3524.
Monclair, T. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report / T. Monclair, G.M. Brodeur, P.F. Ambros et al. // J. Clin. Oncol. - 2009. - Vol. 27. - P. 298-303.
Okcu, M.F. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow / M.F. Okcu, R.Y. Wang, C. Bueso-Ramos et al. // Pediatr. Blood Cancer. - 2005. - Vol. 45. - P. 787-795.
Schmidt, M. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A. retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004 / M. Schmidt, T. Simon, B. Hero et al. // Nuklearmedizin. - 2006. - Vol. 45. - P. 145-151.
Stutterheim, J. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma / J. Stutterheim, A. Gerritsen, L. Zappeij-Kannegieter et al. // J. Clin. Oncol. - 2008. - Vol. 26. - P. 5443-5449.
Stutterheim, J. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers / J. Stutterheim, A. Gerritsen, L. Zappeij-Kannegieter et al. // Clin. Chem. - 2009. - Vol. 55. - P. 1316-1326.
Swerts, K. Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry / K. Swerts, B. De Moerlose, C. Dhooge et al. // Cytometry B Clin Cytometry. - 2004. - Vol. 61B. - P. 9-19.
Swerts, K. Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow / K. Swerts, P.F. Ambros, C. Brouzes et al. // J. Histochem. Cytochem. - 2005. - Vol. 53. - P. 1433-1440.
Tsang, K.S. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction / K.S. Tsang, C.K. Li, W.C. Tsoi et al. // Cancer. - 2003. - Vol. 97. - P. 2887-2897.
Warzynski, M.J. Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients / M.J. Warzynski, D.M. Graham, R.A. Axtell et al. // Cytometry B Clin Cytometry. - 2002. - Vol. 50. - P. 298-304.
Warzynski, M.F. Availability of conjugated ganglioside GD2 monoclonal antibody / M.J. Warzynski, J.L. Roys, J.W. Peterson, H. DeLa Vega // Cytometry B Clin. Cytometry. - 2005. - Vol. 65B. - P. 42-43.
Yanik, G.A. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group / G.A. Yanik, M.T. Parisi, B.L. Shulkin et al. // J. Nucl. Med. - 2013. - Vol. 54. - P. 541-548.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...